The Los Angeles Business Journal announced today that Cord Blood America, Inc. (CBAI.OB) has been ranked as the 20th largest biotech/biomed company in Los Angeles. Cord Blood went public in 2003 and is the second youngest public company to be included on the list, with annual revenues of $6 million and 15 employees.
Cord Blood focuses on educating and assisting families in the benefits of storing life saving stem cells found in umbilical cords. Umbilical cord stem cells have successfully treated more than 70 medical conditions including leukemia, Hodgkin’s Disease, and anemia. Cord Blood provides 24/7 customer support with a full-time physician available for consultation and comprehensive testing, as well as a medical kit with supplies for collecting a newborn’s umbilical cord blood and packaging for transportation. The company’s mission is to become the most respected stem cell preservation company in the industry.
Matthew Schissler, CEO and Founder of Cord Blood America, said, “Our growth has both been rapid and extraordinary. It is nice to see the Company recognized for its achievements and we are proud of what we have accomplished in such a short period of time.”
Let us hear your thoughts: Cord Blood America Inc. Message Board